JP2015520241A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520241A5
JP2015520241A5 JP2015518599A JP2015518599A JP2015520241A5 JP 2015520241 A5 JP2015520241 A5 JP 2015520241A5 JP 2015518599 A JP2015518599 A JP 2015518599A JP 2015518599 A JP2015518599 A JP 2015518599A JP 2015520241 A5 JP2015520241 A5 JP 2015520241A5
Authority
JP
Japan
Prior art keywords
composition
indirubin
surface stabilizer
average particle
effective average
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015518599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520241A (ja
JP6382187B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/046981 external-priority patent/WO2013192493A1/en
Publication of JP2015520241A publication Critical patent/JP2015520241A/ja
Publication of JP2015520241A5 publication Critical patent/JP2015520241A5/ja
Application granted granted Critical
Publication of JP6382187B2 publication Critical patent/JP6382187B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015518599A 2012-06-21 2013-06-21 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 Active JP6382187B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662469P 2012-06-21 2012-06-21
US61/662,469 2012-06-21
PCT/US2013/046981 WO2013192493A1 (en) 2012-06-21 2013-06-21 Nanoparticles of indirubin, derivatives thereof and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018144837A Division JP2018199685A (ja) 2012-06-21 2018-08-01 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法

Publications (3)

Publication Number Publication Date
JP2015520241A JP2015520241A (ja) 2015-07-16
JP2015520241A5 true JP2015520241A5 (enExample) 2016-08-12
JP6382187B2 JP6382187B2 (ja) 2018-08-29

Family

ID=49769412

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015518599A Active JP6382187B2 (ja) 2012-06-21 2013-06-21 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2018144837A Pending JP2018199685A (ja) 2012-06-21 2018-08-01 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2020001832A Pending JP2020073564A (ja) 2012-06-21 2020-01-09 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2021118361A Pending JP2021181447A (ja) 2012-06-21 2021-07-19 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2023021518A Pending JP2023062070A (ja) 2012-06-21 2023-02-15 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018144837A Pending JP2018199685A (ja) 2012-06-21 2018-08-01 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2020001832A Pending JP2020073564A (ja) 2012-06-21 2020-01-09 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2021118361A Pending JP2021181447A (ja) 2012-06-21 2021-07-19 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2023021518A Pending JP2023062070A (ja) 2012-06-21 2023-02-15 インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法

Country Status (6)

Country Link
US (3) US10039829B2 (enExample)
EP (2) EP3597178A1 (enExample)
JP (5) JP6382187B2 (enExample)
CN (2) CN110123763A (enExample)
CA (1) CA2914782C (enExample)
WO (1) WO2013192493A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3597178A1 (en) * 2012-06-21 2020-01-22 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
EP3082803A4 (en) * 2013-12-20 2017-05-31 Phosphorex Inc. Indirubin solid dispersion composition
RU2630561C2 (ru) * 2015-10-20 2017-09-11 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Способ получения водно-солевых дисперсий фуллерена
JP2020515598A (ja) * 2017-03-29 2020-05-28 フォスフォレックス，インコーポレーテッド インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法
RU2721318C1 (ru) * 2019-02-28 2020-05-18 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ получения золей и суспензий
JP2022531012A (ja) * 2019-05-03 2022-07-05 アゾーラ セラピューティクス，インコーポレイテッド インジゴ及び／又はインジゴ誘導体を含む組成物並びにその使用の方法
CN114668744A (zh) * 2022-03-23 2022-06-28 成都大学 一种靛玉红固体脂质纳米粒及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929242A (en) * 1986-11-26 1990-05-29 Baxter International Inc. Solution and method for maintaining patency of a catheter
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
CA2469649C (en) * 2001-12-13 2011-05-03 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
ATE343376T1 (de) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
DE602004024963D1 (de) * 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
CN1615852A (zh) * 2003-11-10 2005-05-18 许军 靛玉红口服滴丸及制备工艺
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
SG161203A1 (en) * 2004-12-15 2010-05-27 Elan Pharma Int Ltd Nanoparticulate tacrolimus formulations
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
CA2594332A1 (en) * 2005-01-06 2006-07-13 Elan Pharma International Ltd. Nanoparticulate candesartan formulations
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
EA200701997A1 (ru) * 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиция из наночастиц бисфосфоната
AU2006226887A1 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
WO2006110802A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
JP2008545752A (ja) * 2005-06-02 2008-12-18 テルシカ インコーポレーティッド 成長障害を処置するための方法
CN101023944A (zh) * 2006-02-23 2007-08-29 黎明涛 靛玉红衍生物在制备治疗神经退行性变疾病药物中的应用
CN101074229B (zh) 2007-06-08 2010-09-01 无锡杰西医药科技有限公司 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US20090274621A1 (en) * 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
CN101362066B (zh) * 2008-09-27 2010-12-22 同济大学 脂质体包埋量子点的二氧化硅微球的制备方法及其产品
CN101775082B (zh) * 2010-02-09 2012-06-27 中国药科大学 基于两性离子的电荷反转型壳聚糖衍生物及其在药剂中的应用
CN102018736B (zh) * 2010-11-19 2012-03-28 成都中医药大学 一种青黛饮片及其制备方法
CN102228433B (zh) * 2011-06-29 2012-11-28 上海中医药大学 过饱和自微乳制剂及其制备方法和应用
EP3597178A1 (en) * 2012-06-21 2020-01-22 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same

Similar Documents

Publication Publication Date Title
JP2015520241A5 (enExample)
JP2017537985A5 (enExample)
RU2017146716A (ru) Способ образования наночастиц циклоспорина а/ циклодекстрина
CN105902496B (zh) 一种纳米混悬液固体化过程的处理方法
JP6054380B2 (ja) 有機化合物ナノ粉体、その製造方法ならびに懸濁液
Gupta et al. Nanoparticles laden in situ gel for sustained ocular drug delivery
JP2020073564A5 (enExample)
JP2017505822A5 (enExample)
EP2790733A2 (en) Nanoparticles with enhanced mucosal penetration or decreased inflammation
WO2013132457A3 (en) Nanocrystalline solid dispersion compositions and process of preparation thereof
JP2011525477A5 (enExample)
JP2013542205A5 (enExample)
JP2016512527A5 (enExample)
CN104224723A (zh) 一种泊马度胺纳米粒、制剂及其制备方法
TWI589301B (zh) 含有碳苯乙烯基衍生物與聚矽氧油及／或聚矽氧油衍生物之懸浮液以及塊體組成物
JP2017517551A5 (enExample)
JP2016507526A5 (enExample)
JP2017526697A5 (enExample)
Papdiwal et al. Investigation of effect of different stabilizers on formulation of zaltoprofen nanosuspension
JP2008538751A5 (enExample)
CN106999429B (zh) 纳米悬浮剂制剂
MX375187B (es) Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo ligadas a partículas portadoras.
Tyagi et al. Smart innovative approach for designing fluvoxamine loaded bio-nanosuspension for the management of depression
JP2015534970A5 (enExample)
Papdiwal et al. Formulation and characterization of nateglinide nanosuspension by precipitation method